Investors Can Lead Class Action Against Humacyte for Securities Fraud

LOS ANGELES, Dec. 5, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) has announced that investors who suffered significant losses may have the chance to lead a class action lawsuit against Humacyte, Inc. (“Humacyte” or the “Company”) HUMA.

Class Period: May 10, 2024 – October 17, 2024
Lead Plaintiff Deadline: January 17, 2025

Interested investors can step up as lead plaintiff by providing their contact information at www.glancylaw.com/cases/Humacyte-Inc/. For more details on their rights, they can reach out to Charles H. Linehan from GPM at 310-201-9150, toll-free at 888-773-9224, or via email at shareholders@glancylaw.com.

The lawsuit alleges that during the Class Period, Defendants did not inform investors that: (1) the Company’s facility in Durham, North Carolina did not meet good manufacturing practices, particularly regarding quality assurance and microbial testing; (2) the FDA’s review of the Biologics License Application (BLA) would be delayed while Humacyte addressed these issues; (3) there was a significant risk to obtaining FDA approval for ATEV, intended for vascular trauma; and (4) as a result, the Defendants’ positive statements about the Company’s operations were misleading or without a reasonable basis.

For future updates, follow Glancy Prongay & Murray LLP on LinkedIn, Twitter, or Facebook.

To be part of the class action, no immediate action is needed. Individuals can choose to retain counsel or remain passive class members. For more details about this class action, or if you have any questions about your rights or interests in the lawsuit, you may contact Charles Linehan, Esquire at GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, toll-free at 888-773-9224, or via email at shareholders@glancylaw.com. Please provide your mailing address, phone number, and number of shares purchased if you reach out by email.

This press release may be considered Attorney Advertising in some jurisdictions based on applicable laws and ethical standards.

Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

View original content to download multimedia:Original Content

SOURCE Glancy Prongay & Murray LLP